A new psilocybin study of 24 adults with depression finds that the psychedelic substance psilocybin, together with therapy, quicky relieved the depressive symptoms in most participants. Psilocybin is a compound found in so-called “magic mushrooms.”
The findings of this psilocybin depression study appeared on November 4 in the journal JAMA Psychiatry.
Effect of psilocybin 4x stronger than traditional antidepressants
As the paper explains, “the effect sizes reported in this study were approximately 2.5 times greater than the effect sizes found in psychotherapy, and more than 4 times greater than the effect sizes found in psycho-pharmacological depression treatment studies.”
The side effects of psilocybin are more limited than those of conventional antidepressants,. These include headaches and some emotional unrest during the sessions. The side effects of antidepressants, on the other hand, have more far-reaching side effects. These include suicidal ideation, decrease in sexual drive, and weight gain.
And psilocybin therapy seems to work after only one or two doses, whereas antidepressants usually need to be taken every day.
Compared to ketamine, another psychoactive substance that has recently been found to alleviate depression, psilocybin has several advantages. The antidepressant effects of psilocybin seem to last longer. Psilocybin also has a lower potential for addiction and adverse events than ketamine.
Two five-hour psilocybin sessions
This new psilocybin study involved 24 subjects who had suffered from depression for a longer period, on average about two years. Their average age was 39.
Each participant took part in two sessions, supervised by the researchers. The sessions lasted about five hours each.
A very large reduction in depressive symptoms
The subjects all completed the GRID-Hamilton Depression Rating Scale. On this scale, a score of 24 or higher means severe depression, and 17-23 means moderate depression, Lower scores of 8-16 indicate mild depression, and 7 or less signifies no depression.
When the study began, the subjects’ average score was 23 — in other words, pretty close to severe. But when they took the assessment again 4 weeks later, their average score had dropped to 8 — meaning almost no depression.
The researchers plan to follow the subjects for the next year, and will report on the long-term results in a future psilocybin study.
Major depressive disorder
Major depressive disorder is the commonest of the mental illnesses. It is a disorder of mood often characterized by sadness, loneliness, loss of interest (anhedonia), loss of energy (asthenia), distractedness, and loss of self-esteem. Depression is a serious mental illness that affects millions of people, and sometimes causes severe symptoms that interfere with daily life and work.
More recent science and psychology news:
- Did you know that 13% of people are pathological liars, who tell on average 10 lies per day?
- Can dogs get diabetes? Yes, and a new study shows that owners of a diabetic dog are 38% more likely to have diabetes themselves.
- This new dog personality test shows that dogs tend to grow less curious with age, but also more attached to their owners.
- A new analysis of Trump sleep patterns shows he’s been sleeping less. This is hurting his performance, and making him angrier.
- A new study finds that a 30-minute “empathy exercise” for the urban parole officer led to a 13% reduction in parolees’ recidivism rates 10 months later.
Study: “Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial“
Authors: Alan K. Davis, Frederick S. Barrett, Darrick G. May, Mary P. Cosimano, Nathan D. Sepeda, Matthew W. Johnson, Patrick H. Finan, and Roland R. Griffiths
Published in: JAMA Psychiatry
Publication date: November 4, 2020
Photo: by James Bak via Unsplash